Sivakesava Sakhamuri filed a Form 3 initial statement of beneficial ownership with the SEC on November 2, 2026, disclosing his status as Chief Technical Officer of CRISPR Therapeutics AG (NASDAQ:CRSP) and reporting no securities beneficially owned.

Key Highlights

  • New officer filing: Sivakesava Sakhamuri submitted an initial statement of beneficial ownership as Chief Technical Officer of CRISPR Therapeutics AG.
  • Event date: The date of the event requiring the statement was November 2, 2026.
  • No securities held: The filing states, "No securities are beneficially owned," with both Table I (non-derivative securities) and Table II (derivative securities) left blank.
  • Officer role confirmed: Sakhamuri is identified as an officer, with the title Chief Technical Officer, and is not listed as a director or 10% owner.
  • Individual filing: The form was filed by one reporting person, with Sakhamuri's address listed as c/o CRISPR Therapeutics, 105 West First Street, Boston, Massachusetts 02127.

Sakhamuri's Initial Ownership Disclosure at CRISPR Therapeutics

According to the filing, Sivakesava Sakhamuri submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - in connection with his role as Chief Technical Officer at CRISPR Therapeutics AG. The event requiring the statement is dated November 2, 2026, which is also the date on which the form was signed and filed.

The filing discloses that Sakhamuri holds no securities in CRISPR Therapeutics AG at the time of the filing. Both Table I, covering non-derivative securities such as common shares, and Table II, covering derivative securities such as options or warrants, contain no entries. The filing includes the explicit note: "No securities are beneficially owned." No indirect holdings or holdings through other persons or entities are reported.

Sakhamuri's relationship to the issuer is identified solely as an officer, with the specific title of Chief Technical Officer. He is not indicated to be a director or a 10% owner. The form was filed by one reporting person and was signed by Sivakesava Sakhamuri on November 2, 2026.

What Was Disclosed

Sivakesava Sakhamuri filed an initial beneficial ownership statement upon becoming Chief Technical Officer of CRISPR Therapeutics AG, reporting no direct or indirect beneficial ownership of any securities, including no derivative securities, as of November 2, 2026.